A Pharmaceopidemiological Study in Patients Who Use Symbicort SMART

This study is currently recruiting participants.

Verified by AstraZeneca, April 2009

First Received: July 17, 2007 Last Updated: April 3, 2009 History of Changes

Sponsored by:	AstraZeneca
Information provided by:	AstraZeneca
ClinicalTrials.gov Identifier:	NCT00503061

Purpose

To investigate how common it is that patients using Symibort SMART take high average daily doses that are not considered appropriate by their physician (overuse) or are hospitalised due to their asthma at least partly due to underuse.

Condition
Bronchial Asthma

MedlinePlus related topics: Asthma

Drug Information available for: Symbicort

U.S. FDA Resources

Study Type:	Observational
Study Design:	Case-Only, Prospective
Official Title:	A Pharmaceopidemiological Study in Patients Who Use Symbicort Turbuhaler as Maintenance and Reliever Therapy (Symibort SMART) Capturing Over Use and Under Use Via the General Practice Research Database

Further study details as provided by AstraZeneca:

Estimated Enrollment:	1000
Study Start Date:	July 2007
Estimated Study Completion Date:	December 2009

Eligibility

Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Asthma diagnosis, patient registered with the prescribing physician for at least one year before the qualifying prescription of Symbicort, prescription of Symbicort SMART after UK launch of the concept

Exclusion Criteria:

None

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00503061

Contacts

Contact: AstraZeneca Clinical Study, Information	1-800-236-9933	information.center@astrazeneca.com
Contact: AstraZeneca Information (Outside, US)	001-800-236-9933

Locations

United Kingdom
Research Site	Recruiting
London, United Kingdom

Sponsors and Collaborators

AstraZeneca

Investigators

Principal Investigator:	Catriona McMahon, MD	AZ UK MC
Study Director:	Tomas Andersson, MD	AZ R&D Lund

More Information

Additional Information:

Related Info This link exits the ClinicalTrials.gov site

No publications provided

Study ID Numbers:	D5890C00017, GPRD
Study First Received:	July 17, 2007
Last Updated:	April 3, 2009
ClinicalTrials.gov Identifier:	NCT00503061 History of Changes
Health Authority:	United Kingdom: Independent Scientific Advisory Committee

Keywords provided by AstraZeneca:

pharmaceopidemiological
Symbicort SMART
GPRD

Study placed in the following topic categories:

Hypersensitivity
Lung Diseases, Obstructive
Symbicort
Respiratory Tract Diseases
Bronchial Diseases

Lung Diseases
Hypersensitivity, Immediate
Anti-Asthmatic Agents
Asthma
Respiratory Hypersensitivity

Additional relevant MeSH terms:

Respiratory System Agents
Bronchial Diseases
Immune System Diseases
Symbicort
Asthma
Anti-Asthmatic Agents
Pharmacologic Actions

Lung Diseases, Obstructive
Hypersensitivity
Respiratory Tract Diseases
Lung Diseases
Therapeutic Uses
Hypersensitivity, Immediate
Respiratory Hypersensitivity

ClinicalTrials.gov processed this record on May 07, 2009